As many as 11 million people in the United States have some form of age-related macular degeneration. This number is expected to double to nearly 22 million by 2050. The impact of age-related macular degeneration on the global aging population is enormous as people are deprived of their economic livelihoods and independence.
Eye and vision researchers have already discovered several genes at work in AMD, the distinctions between types of AMD and the development of therapeutic remedies. The ARVO Foundation for Eye Research believes the work must continue so that there can be earlier identification of those likely to develop AMD, discovery of ways to slow the progression of the disease and novel ways to treat AMD to limit sight loss. Thanks to Genentech's support, the ARVO Foundation will offer one grant to a researcher working in basic research in the understanding of AMD and another grant to a researcher working in translational AMD research focusing on therapeutics. Each research fellowship (basic and translational) is $40,000.
Applications are now closed.
Learn more about eligibility and application details
2017 Genentech AMD Research Fellowship recipients
Eiko de Jong, MSc, PhD (Basic)
Proteomic profiling of high-density lipoprotein particles in AMD patients
Sonali Nashine, PhD (Translational)
University of California, Irvine
Protecting AMD cybrid cells using mitochondrial-derived peptides and FDA-approved mitochondria stabilizing drugs; Implications for macular degeneration therapeutics